Access cutting-edge prostate cancer treatment through this clinical trial at a research site in Palo Alto. Study-provided care at no cost to qualified participants.
Access prostate cancer specialists in Palo Alto at no cost
This study follows strict safety protocols and ethical guidelines
All study-related prostate cancer treatment provided free
This is a phase 3, randomized, open-label study of opevesostat compared to alternative abiraterone acetate or enzalutamide in participants with metastatic castration-resistant prostate cancer (mCRPC) with respect to overall survival (OS) in participants with mCRPC previously treated with next-generation hormonal agent (NHA) and taxane-based chemotherapy. It is hypothesized that opevesostat is superior with respect to OS in androgen receptor ligand binding domain (AR LBD) mutation-negative and -p
Sponsor: Merck Sharp & Dohme LLC
Check if you qualify for this prostate cancer clinical trial in Palo Alto, CA
If you're searching for prostate cancer treatment options in Palo Alto, CA, this clinical trial may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.
Our Palo Alto research site is actively enrolling participants for this clinical trial. You'll receive care from experienced prostate cancer specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.